Hans‐Juergen Woerle

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Ele Ferrannini, Elza Muscelli, Silvia Frascerra et al. · Journal of Clinical Investigation · 2014 · 1.1K citations · Full text

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou et al. · Cardiovascular Diabetology · 2014 · 458 citations · Full text

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

Baptist Gallwitz, Julio Rosenstock, T. Rauch et al. · The Lancet · 2012 · 336 citations

Non-pharmacological Intervention, Diabetes Management, Health Policy +9

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic et al. · Diabetes Care · 2013 · 295 citations · Full text

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Bernard Zinman, Silvio E. Inzucchi, John M. Lachin et al. · Cardiovascular Diabetology · 2014 · 247 citations · Full text